Eight drugmakers agreed to put legal claims stemming from their roles in the U.S. | Viatris, Hikma, Amneal, Apotex, Indivior, ...

While Astellas’ Veozah was the first neurokinin 3 (NK-3) receptor antagonist approved for menopause, Lynkuet is the first ...

In the latest twist in the ocean of Zantac-related litigation playing out across state courts, drugmakers have notched a key ...

Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...

After years of investment to upgrade its manufacturing capabilities, Pacira BioSciences figures it’s time to retire a facility that has been running for more than a decade. | After years spent ...

According to a pair of recent rulings by the U.K.’s Prescription Medicines Code of Practice Authority (PMCPA), Jazz ...

After reporting a 15% sequential decline in Izervay sales for the opening quarter of this year, Astellas has reversed the ...

Nearly 70 years into her history, Barbie is still undergoing regular makeovers. | Nearly 70 years into her history, Barbie is ...

Already late with carrying out his administration's prior threats around pharmaceutical tariffs, President Donald Trump has ...

The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...

China’s first domestically made nine-valent HPV vaccine, a direct competitor to Merck’s Gardasil 9, is being priced at 499 ...

Renee Gala joins a short list of female biopharma chief executives as she is set to take the reins at Jazz Pharmaceuticals, ...